Drug Type CIK therapy |
Synonyms activated CIK/anti-CD3-MUC1 bispecific antibody |
Target |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), MUC1 inhibitors(Mucin-1 inhibitors), CIK cells replacements(Cytokine-induced killer cells replacements) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Pancreatic Adenocarcinoma | Phase 2 | CN | 12 Apr 2018 | |
Kidney Neoplasms | Phase 2 | CN | 10 Apr 2018 | |
Advanced gastric carcinoma | Phase 2 | CN | 05 Apr 2018 | |
Lung Cancer | Phase 2 | CN | 27 Mar 2018 | |
Liver Cancer | Phase 2 | CN | 01 May 2017 |
NCT03146637 (ASCO2021) Manual | Phase 1 | 11 | hmiokohmbu(xdwzpazwuu) = xtpdgoyoyd isedvxekfs (oilngmlukx ) View more | Positive | 28 May 2021 |